The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“A specific Raf kinase, B-Raf, is mutated in two-thirds of melanomas and a small percentage of colorectal and other solid tumors (Davies et al., 2002).”
BackgroundCell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,490
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 2×
“Multiple cytoplasmic signaling pathways, including the Ras/ Raf mitogen-activated protein kinase pathway, the phosphoinositol 3 -kinase/Akt pathway, the signal transducer and activator of transcription 3 pathway, the protein kinase C pathway, and scaffolding proteins may then be activated (Schlessinger, 2000; Bogdan a…”
BackgroundBlume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 3×
“Drug resistance is usually associated with the reactivation of BCR-ABL signal transduction, but BCR-ABL gene amplification and overexpression of protein is also associated with drug resistance both in vitro and in vivo (Gorre et al., 2001; Tsao et al., 2002).”
BackgroundEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
Cited by
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Sunitinib: From Rational Design to Clinical Efficacy
Chow, L. Q. M., & Eckhardt, S. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3602 · Cited by 883
Glioblastoma multiforme: Pathogenesis and treatment
Alifieris, C., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 820
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
In vivo delivery of miRNAs for cancer therapy: Challenges and strategies
Chen, Y., Gao, D.-Y., & Huang, L. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.009 · Cited by 672
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Shen, G., Zheng, F., Ren, D., Du, F., Dong, Q., Wang, Z., Zhao, F., Ahmad, R., & Zhao, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0664-7 · Cited by 658
Sabbah, D. A., Hajjo, R., & Sweidan, K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200303123102 · Cited by 591
HCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 564
Relaxin family peptides and their receptors
Bathgate, R. A. D., Halls, M. L., van der Westhuizen, E. T., Callander, G. E., Kocan, M., & Summers, R. J. (2013) · Physiological Reviews · doi:10.1152/physrev.00001.2012 · Cited by 534
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies
Yewale, C., Baradia, D., Vhora, I., Patil, S., & Misra, A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.100 · Cited by 533
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
The Epidermal Growth Factor Receptor System in Skin Repair and Inflammation
Pastore, S., Mascia, F., Mariani, V., & Girolomoni, G. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701184 · Cited by 443
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
Pienta, K. J., & Bradley, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0067 · Cited by 430
Anaplastic lymphoma kinase: signalling in development and disease
Palmer, R. H., Vernersson, E., Grabbe, C., & Hallberg, B. (2009) · Biochemical Journal · doi:10.1042/bj20090387 · Cited by 423
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT
Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007258 · Cited by 421
“Imatinib mesylate (Gleevec, STI-571; Novartis, Basel, Switzerland) was the first TK inhibitor approved for clinical use [7].”
BackgroundAn overview of small-molecule inhibitors of VEGFR signaling
Ivy, S. P., Wick, J. Y., & Kaufman, B. M. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.130 · Cited by 350
Yap, T. A., Vidal, L., Adam, J., Stephens, P., Spicer, J., Shaw, H., Ang, J., Temple, G., Bell, S., Shahidi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7278 · Cited by 349
Shi, Z., Peng, X.-X., Kim, I.-W., Shukla, S., Si, Q.-S., Robey, R. W., Bates, S. E., Shen, T., Ashby, C. R., Fu, L.-W., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2686 · Cited by 315
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
Ballester, B., Milara, J., & Cortijo, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030593 · Cited by 308
Mechanisms for oncogenic activation of the epidermal growth factor receptor
Zandi, R., Larsen, A. B., Andersen, P., Stockhausen, M.-T., & Poulsen, H. S. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.06.023 · Cited by 303
Henson, E. S., & Gibson, S. B. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.05.015 · Cited by 300
The Prodrug Approach: A Successful Tool for Improving Drug Solubility
Jornada, D., Dos Santos Fernandes, G., Chiba, D., De Melo, T., Dos Santos, J., & Chung, M. (2015) · Molecules · doi:10.3390/molecules21010042 · Cited by 294
Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 294
Hepatocellular Carcinoma: Etiology and Current and Future Drugs
Jindal, A., Thadi, A., & Shailubhai, K. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.01.004 · Cited by 257
Anticancer strategies involving the vasculature
Heath, V. L., & Bicknell, R. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.52 · Cited by 255
Targeted nanoparticles for detecting and treating cancer
Sunderland, C. J., Steiert, M., Talmadge, J. E., Derfus, A. M., & Barry, S. E. (2006) · Drug Development Research · doi:10.1002/ddr.20069 · Cited by 200
Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport
Braun, D., Kim, T. D., le Coutre, P., Köhrle, J., Hershman, J. M., & Schweizer, U. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1837 · Cited by 102
Progress toward Overcoming Hypoxia-Induced Resistance to Solid Tumor Therapy
Reginato, M., & Karakashev, S. (2015) · Cancer Management and Research · doi:10.2147/cmar.s58285 · Cited by 95
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Bahl, S., & Seto, E. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03599-4 · Cited by 82
Presence and utility of intrinsically disordered regions in kinases
Kathiriya, J. J., Pathak, R. R., Clayman, E., Xue, B., Uversky, V. N., & Davé, V. (2014) · Molecular BioSystems · doi:10.1039/c4mb00224e · Cited by 30
Hay, I. M., Mulholland, K. E., Lai, T., Graham, S. C., Sharpe, H. J., & Deane, J. E. (2022) · eLife · doi:10.7554/elife.79855 · Cited by 3
Metadata
- Authors
- Arora, A., & Scholar, E. M.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2005-12
- Volume
- 315
- Issue
- 3
- Pages
- 971-979
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W1974903851
- Cited by
- 1,014
- References
- 72
- FWCI
- 24.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.